These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23105832)

  • 1. Study of oxidative stress in obsessive compulsive disorder in response to treatment with Fluoxetine.
    Chakraborty S; Dasgupta A; Das HN; Singh OP; Mandal AK; Mandal N
    Indian J Clin Biochem; 2009 Apr; 24(2):194-7. PubMed ID: 23105832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder.
    Chakraborty S; Singh OP; Dasgupta A; Mandal N; Nath Das H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):363-6. PubMed ID: 19272303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.
    Costa DLDC; Barbosa VS; Requena G; Shavitt RG; Pereira CAB; Diniz JB
    J Psychopharmacol; 2017 Oct; 31(10):1312-1322. PubMed ID: 28441896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
    Yoosefee S; Amanat M; Salehi M; Mousavi SV; Behzadmanesh J; Safary V; Yoonesi A; Salehi B
    BMC Psychiatry; 2020 Nov; 20(1):570. PubMed ID: 33256659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine.
    Agarwal V; Agarwal KM
    Indian J Psychiatry; 2000 Jul; 42(3):291-4. PubMed ID: 21407959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it time to change the gold standard of obsessive-compulsive disorder severity assessment? Factor structure of the Yale-Brown Obsessive-Compulsive Scale.
    Fatori D; Costa DL; Asbahr FR; Ferrão YA; Rosário MC; Miguel EC; Shavitt RG; Batistuzzo MC
    Aust N Z J Psychiatry; 2020 Jul; 54(7):732-742. PubMed ID: 32475123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Yale-Brown Obsessive Compulsive Scale. II. Validity.
    Goodman WK; Price LH; Rasmussen SA; Mazure C; Delgado P; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1989 Nov; 46(11):1012-6. PubMed ID: 2510699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep brain stimulation for severe treatment-resistant obsessive-compulsive disorder: An open-label case series.
    Farrand S; Evans AH; Mangelsdorf S; Loi SM; Mocellin R; Borham A; Bevilacqua J; Blair-West S; Walterfang MA; Bittar RG; Velakoulis D
    Aust N Z J Psychiatry; 2018 Jul; 52(7):699-708. PubMed ID: 28965430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial.
    Sabetnejad Z; Assarian F; Omidi A; Najarzadegan MR
    Electron Physician; 2016 Nov; 8(11):3156-3163. PubMed ID: 28070247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of specific obsessive-compulsive symptom dimensions on strategic planning in patients with obsessive-compulsive disorder.
    Pinto PS; Iego S; Nunes S; Menezes H; Mastrorosa RS; Oliveira IR; Rosário MC
    Braz J Psychiatry; 2011 Mar; 33(1):40-6. PubMed ID: 21537721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Study of Neurological Soft Signs in Patients with Schizophrenia or Obsessive-compulsive Disorder, and Healthy Controls.
    Tripathi R; Soni A; Tyagi A; Mehta S; Gupta S
    East Asian Arch Psychiatry; 2015 Jun; 25(2):64-72. PubMed ID: 26118745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.
    Goodman WK; Price LH; Rasmussen SA; Mazure C; Fleischmann RL; Hill CL; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1989 Nov; 46(11):1006-11. PubMed ID: 2684084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.
    Romano S; Goodman W; Tamura R; Gonzales J
    J Clin Psychopharmacol; 2001 Feb; 21(1):46-52. PubMed ID: 11199947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine Oxidase A Hypomethylation in Obsessive-Compulsive Disorder: Reversibility By Successful Psychotherapy?
    Schiele MA; Thiel C; Deckert J; Zaudig M; Berberich G; Domschke K
    Int J Neuropsychopharmacol; 2020 May; 23(5):319-323. PubMed ID: 32133483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Yale-Brown Scale: instrument for assessing the severity of obsessive-compulsive disorders].
    Kiejna A; Grzesiak M; Małyszczak K
    Psychiatr Pol; 1998; 32(1):69-76. PubMed ID: 9594585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
    Tollefson GD; Rampey AH; Potvin JH; Jenike MA; Rush AJ; kominguez RA; Koran LM; Shear MK; Goodman W; Genduso LA
    Arch Gen Psychiatry; 1994 Jul; 51(7):559-67. PubMed ID: 8031229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.